2189 |
Renal Denervation and Treatment of Hypertension: Clinical Update |
Horst Sievert |
May. 09. 14 |
2188 |
How Should LAA Closure Devices Be Integrated into Clinical Practice? |
David R. Holmes |
May. 09. 14 |
2187 |
New Pharmacologic Agents to Treat Atrial Fibrillation |
Sorin Brener |
May. 09. 14 |
2186 |
New TAVR Systems and Accessory Devices |
Martin Bert Leon |
May. 09. 14 |
2185 |
Beyond High-risk Patients: Will TAVR Replace Surgical AVR? |
Eberhard Grube |
May. 09. 14 |
2184 |
Interventional Cardiovascular Medicine: Past, Now and Future Perspectives |
Martin Bert Leon |
May. 09. 14 |
2183 |
Medical Treatment After Endovascular Therapy: Focus on STOP-IC |
Hiroyoshi Yokoi |
May. 09. 14 |
2182 |
Medical Treatment of Symptomatic PAD: The Role of Cilostazol |
Seung-Whan Lee |
May. 09. 14 |
2181 |
The Role of PAQ (Peripheral Artery Questionnaire) |
Kyoung Im Cho |
May. 09. 14 |
2180 |
Drug-coated Balloons for Treatment of Coronary Artery Disease: Updated Recommendations from a Consensus Group |
Franz X. Kleber |
May. 09. 14 |